Elevated CSF levels of matrix metalloproteinase‐12 as a potential marker for microhemorrhage risk in autosomal dominant Alzheimer disease

Abstract

Background: With the advent of disease‐modifying treatment for Alzheimer disease (AD), identifying biomarkers for predicting risk for amyloid‐related imaging abnormalities (ARIA), hemorrhagic or edema types, is of increased interest.

The paper